| scholarly article | Q13442814 |
| meta-analysis | Q815382 |
| P50 | author | Yoon K Loke | Q48100165 |
| Sonal Singh | Q37604126 | ||
| Chun Shing Kwok | Q37841809 | ||
| P2093 | author name string | Chen Chen-Turner | |
| Chinedu A Maduakor | |||
| Richard M Turner | |||
| P2860 | cites work | Pioglitazone--do we really need it to manage type 2 diabetes? | Q38091789 |
| Scientific Evidence and Controversies About Pioglitazone and Bladder Cancer: Which Lessons Can Be Drawn? | Q38122640 | ||
| When can odds ratios mislead? | Q41742782 | ||
| Effects of pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, on the urine and urothelium of the rat. | Q43254579 | ||
| Neoplastic and non-neoplastic changes in F-344 rats treated with Naveglitazar, a gamma-dominant PPAR alpha/gamma agonist | Q43287595 | ||
| Liver safety in patients with type 2 diabetes treated with pioglitazone: results from a 3-year, randomized, comparator-controlled study in the US. | Q43294072 | ||
| Diabetes and risk of bladder cancer: a study using the National Health Insurance database in Taiwan | Q43748015 | ||
| Risk of bladder cancer in diabetic patients treated with rosiglitazone or pioglitazone: a nested case–control study | Q44980532 | ||
| Rosiglitazone, a PPAR gamma agonist: potent promoter of hydroxybutyl(butyl)nitrosamine-induced urinary bladder cancers | Q46422710 | ||
| Urothelial carcinogenesis in the urinary bladder of rats treated with naveglitazar, a gamma-dominant PPAR alpha/gamma agonist: lack of evidence for urolithiasis as an inciting event | Q46599209 | ||
| Increased risk of bladder cancer with pioglitazone therapy in patients with diabetes: a meta-analysis | Q47613876 | ||
| Analysing Data and Undertaking Meta-Analyses | Q58642714 | ||
| Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus | Q59656664 | ||
| Pioglitazone and bladder cancer | Q82248231 | ||
| Stay vigilant: a glitazone (pioglitazone) can hide a glitazar! | Q84108503 | ||
| More on influenza vaccine in young children | Q84470306 | ||
| Possible link of pioglitazone with bladder cancer in Japanese patients with type 2 diabetes | Q85642529 | ||
| Rosiglitazone is not associated with an increased risk of bladder cancer | Q86658068 | ||
| FDA panel advises easing restrictions on rosiglitazone | Q86927553 | ||
| Flip flop policy over pioglitazone licence causes media storm in India | Q87209222 | ||
| The appropriateness of asymmetry tests for publication bias in meta-analyses: a large survey | Q24282603 | ||
| Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis | Q24655666 | ||
| Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial | Q29619886 | ||
| Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy | Q29620534 | ||
| Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive | Q33425406 | ||
| Suppressive effects of acid-forming diet against the tumorigenic potential of pioglitazone hydrochloride in the urinary bladder of male rats | Q33800079 | ||
| Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical t | Q34023560 | ||
| Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone | Q34123137 | ||
| Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies | Q34324440 | ||
| Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. | Q34510811 | ||
| Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. | Q34628009 | ||
| Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials | Q34686089 | ||
| Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial | Q34766176 | ||
| Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial | Q34985342 | ||
| Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting | Q35043204 | ||
| When to publish measures of disproportionality derived from spontaneous reporting databases? | Q35629757 | ||
| Pioglitazone and bladder cancer: a population-based study of Taiwanese. | Q35688201 | ||
| The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study | Q36001145 | ||
| Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study | Q36013549 | ||
| Effects of PPARgamma and combined agonists on the urinary tract of rats and other species | Q36210174 | ||
| Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis | Q36247512 | ||
| The risk of bladder cancer in korean diabetic subjects treated with pioglitazone. | Q36365241 | ||
| Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study | Q36486802 | ||
| Pioglitazone and bladder cancer: a propensity score matched cohort study | Q36562522 | ||
| Bladder cancer in 2010: how far have we come? | Q37766697 | ||
| Epidemiology and risk factors of urothelial bladder cancer | Q38033265 | ||
| Examining the safety of PPAR agonists - current trends and future prospects | Q38058381 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | bladder cancer | Q504775 |
| meta-analysis | Q815382 | ||
| systematic review | Q1504425 | ||
| P304 | page(s) | 258-273 | |
| P577 | publication date | 2014-08-01 | |
| P1433 | published in | British Journal of Clinical Pharmacology | Q176044 |
| P1476 | title | Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta-analysis | |
| P478 | volume | 78 |
| Q53684513 | An aPPARent Functional Consequence in Skeletal Muscle Physiology via Peroxisome Proliferator-Activated Receptors. |
| Q38250719 | Antihyperglycaemic therapies and cancer risk |
| Q38838622 | Antineoplastic effects of 15(S)-hydroxyeicosatetraenoic acid and 13-S-hydroxyoctadecadienoic acid in non-small cell lung cancer. |
| Q94683791 | Association between metabolic syndrome and recurrence of nonmuscle-invasive bladder cancer in older adults |
| Q38262803 | Association between metabolic syndrome, obesity, diabetes mellitus and oncological outcomes of bladder cancer: a systematic review |
| Q37176719 | Beneficial effects of combined resveratrol and metformin therapy in treating diet-induced insulin resistance |
| Q37716571 | Characteristics of Chinese herbal medicine usage in ischemic heart disease patients among type 2 diabetes and their protection against hydrogen peroxide-mediated apoptosis in H9C2 cardiomyoblasts |
| Q35877249 | Chinese Herbal Medicine Treatment Improves the Overall Survival Rate of Individuals with Hypertension among Type 2 Diabetes Patients and Modulates In Vitro Smooth Muscle Cell Contractility |
| Q33567551 | Cycling our way to fit fat. |
| Q33781632 | Data-driven prediction of adverse drug reactions induced by drug-drug interactions. |
| Q36712191 | Diabetes Pharmacotherapies and Bladder Cancer: A Medicare Epidemiologic Study |
| Q38651175 | Diabetes drugs and the incidence of solid cancers: a survey of the current evidence. |
| Q49372368 | Diabetes mellitus and the risk of bladder cancer: A PRISMA-compliant meta-analysis of cohort studies. |
| Q38338539 | Diabetic nephropathy: landmark clinical trials and tribulations |
| Q41992140 | Effects of Chinese herbal medicines on the occurrence of diabetic retinopathy in type 2 diabetes patients and protection of ARPE-19 retina cells by inhibiting oxidative stress |
| Q60302268 | Emerging biomarkers for the diagnosis and monitoring of urothelial carcinoma |
| Q30234362 | Epidemiology of urothelial carcinoma |
| Q63984743 | Epidemiology, aetiology and screening of bladder cancer |
| Q47782346 | Genomic Activation of PPARG Reveals a Candidate Therapeutic Axis in Bladder Cancer |
| Q45073276 | Global and Regional Effects of Bladder Cancer Risk Associated with Pioglitazone Therapy in Patients with Diabetes |
| Q90448406 | Identification and structural insight of an effective PPARγ modulator with improved therapeutic index for anti-diabetic drug discovery |
| Q37609686 | Identification of a novel selective PPARγ ligand with a unique binding mode and improved therapeutic profile in vitro. |
| Q50056200 | Impact of regulatory spin of pioglitazone on prescription of antidiabetic drugs among physicians in India: A multicentre questionnaire-based observational study |
| Q28080717 | Improvements in the Management of Diabetic Nephropathy |
| Q47222945 | Laminar shear stress inhibits high glucose-induced migration and invasion in human bladder cancer cells. |
| Q59803344 | Metabolic control of PPAR activity by aldehyde dehydrogenase regulates invasive cell behavior and predicts survival in hepatocellular and renal clear cell carcinoma |
| Q112284336 | Network Pharmacology-Based Study on the Active Component and Mechanism of the Anti-Non-Invasive and Invasive Bladder Urothelial Carcinoma Effects of Zhuling Jisheng Decoction |
| Q41608549 | New botanical drug, HL tablet, reduces hepatic fat as measured by magnetic resonance spectroscopy in patients with nonalcoholic fatty liver disease: A placebo-controlled, randomized, phase II trial |
| Q38543105 | Non-alcoholic fatty liver disease following liver transplantation: a clinical review. |
| Q92853609 | PPARγ-Independent Side Effects of Thiazolidinediones on Mitochondrial Redox State in Rat Isolated Hearts |
| Q57072853 | Peroxisome Proliferator Activated Receptor Agonists Modulate Transposable Element Expression in Brain and Liver |
| Q38455771 | Pharmacokinetics and clinical evaluation of the alogliptin plus pioglitazone combination for type 2 diabetes |
| Q55356554 | Pioglitazone Use and Risk of Bladder Cancer: an In Vitro Study. |
| Q38417421 | Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis |
| Q55079635 | Pioglitazone and bladder cancer risk: a systematic review and meta-analysis. |
| Q37179822 | Pioglitazone use and risk of bladder cancer in patients with type 2 diabetes: retrospective cohort study using datasets from four European countries |
| Q91875408 | Pioglitazone use and risk of bladder cancer: a systematic literature review and meta-analysis of observational studies |
| Q34676639 | Pioglitazone use and risk of bladder cancer: population based cohort study |
| Q55406042 | Pioglitazone use in patients with diabetes and risk of bladder cancer: a systematic review and meta-analysis. |
| Q44338326 | Pioglitazone--when is a prescription drug safe? |
| Q26745900 | Recent advances in managing and understanding diabetic nephropathy |
| Q42135988 | Should we stop prescribing pioglitazone? |
| Q64055525 | Tangduqing Granules Attenuate Insulin Resistance and Abnormal Lipid Metabolism through the Coordinated Regulation of PPAR and DGAT2 in Type 2 Diabetic Rats |
| Q30250347 | The current role of thiazolidinediones in diabetes management |
| Q52594525 | Thiazolidinediones and risk of colorectal cancer in patients with diabetes mellitus: A meta-analysis. |
| Q38264376 | Type 2 diabetes pharmacoepidemiology update 2014: safety versus efficacy |
| Q35684826 | Understanding drug preferences, different perspectives |
Search more.